Blog
RSS FeedPosted by Michael Wonder on 03 Aug 2017
Negative NICE draft guidance for Lutathera
3 August 2017 - UK medicines cost-effectiveness watchdog NICE has today published draft guidance which does not recommend French molecular nuclear ...
Posted by Michael Wonder on 02 Aug 2017
Roche invited to submit a CDF proposal for urothelial cancer drug
2 August 2017 - NICE has asked Roche to submit a Cancer Drugs Fund proposal for an immunotherapy treatment called ...
Posted by Michael Wonder on 31 Jul 2017
NICE bars obesity pill from routine NHS use
31 July 2017 - Cost regulators for NHS treatments in England and Wales are standing by their position that Orexigen’s ...
Posted by Michael Wonder on 27 Jul 2017
£3 a day drug for irritable bowel syndrome gets NICE approval
27 July 2017 - The drug, Truberzi has been recommended for routine funding on the NHS to treat patients with irritable ...
Posted by Michael Wonder on 27 Jul 2017
Statins should be offered to everyone who has chronic kidney disease, says NICE
27 July 2017 - Healthcare professionals should offer statins to millions of people with chronic kidney disease. ...
Posted by Michael Wonder on 26 Jul 2017
Roche hails 4 year NICE access deal for Gazyvaro
26 July 2017 - NICE has agreed a deal with Roche on its new follicular lymphoma treatment Gazyvaro, giving the ...
Posted by Michael Wonder on 26 Jul 2017
NICE approval for nivolumab provides new treatment for advanced blood cancer
26 July 2017 - People with an advanced type of blood cancer will benefit from nivolumab on the NHS following approval ...
Posted by Michael Wonder on 25 Jul 2017
Vismodegib for treatment of patients with basal cell carcinoma
20 July 2017 - The Department of Health has asked the NICE to produce guidance on the use vismodegib in the ...
Posted by Michael Wonder on 24 Jul 2017
NHS England consults on blocking ‘wasteful’ prescriptions
24 July 2017 - NHS England has unveiled detailed proposals of how prescriptions for “ineffective, over-priced and low value treatments” ...
Posted by Michael Wonder on 24 Jul 2017
Managing conflicts of interest – making good decisions
24 July 2017 - NICE is seeking views on a new conflicts of interest policy to ensure its committees’ decisions ...
Posted by Michael Wonder on 23 Jul 2017
Tackling submission and publication bias
17 July 2017 - Evoniuk and colleagues analysed whether submission and publication bias are based on study outcome. ...
Posted by Michael Wonder on 20 Jul 2017
NICE recommends Cinqaero (reslizumab) for the treatment of severe eosinophilic asthma
20 July 2017 - Teva Pharmaceutical Industries today announced that the NICE in England has recommended Cinqaero (reslizumab) in its final ...
Posted by Michael Wonder on 20 Jul 2017
Teva’s Cinqaero to challenge Nucala after clearing NICE
20 July 2017 - NICE has recommended Teva’s treatment for severe asthma Cinqaero, allowing it to challenge GSK’s rival Nucala. ...
Posted by Michael Wonder on 19 Jul 2017
NICE approves more tolerable treatment for blood cancer
19 July 2017 - Around 2,200 patients a year with multiple myeloma are set to benefit from a new, tolerable treatment ...
Posted by Michael Wonder on 17 Jul 2017
How the NHS became embroiled in a global drugs price clash
15 July 2017 - Multinational drug firms were never going to look good taking the NHS to court. ...